LENZ Therapeutics (LENZ) Q4 2024 earnings summary

Executive summary

• Achieved major milestones in 2024, including public listing, completion of Phase 3 CLARITY study, and NDA submission and acceptance for LNZ100, with PDUFA date set for August 8, 2025.

• LNZ100 targets the $3B US presbyopia market, with launch preparations underway and product availability expected in Q4 2025, pending FDA approval.

• Phase 3 trials demonstrated rapid onset, long duration, and high efficacy, with 71% achieving ≥3-line improvement at 3 and 10 hours, and 95% achieving ≥2-line improvement at 1 hour.

• Cash position of $209.1 million as of December 31, 2024, expected to fund operations through post-launch positive cash flow.

• Transitioned to a pre-commercial company, advancing manufacturing, regulatory, and commercial readiness.

Financial highlights

• Ended 2024 with $209.1 million in cash, cash equivalents, and marketable securities.

• Q4 2024 operating expenses were $15.2 million, down from $25 million in Q4 2023, but up 18% sequentially from Q3 2024.

• Q4 2024 SG&A expenses rose to $9.4 million from $5.5 million in Q4 2023, and up 44% sequentially, reflecting commercial ramp-up.

• R&D expenses decreased to $5.9 million in Q4 2024 from $19.5 million in Q4 2023, and $29.8 million for FY 2024 from $59.5 million in FY 2023.

• Q4 2024 net loss was $12.7 million ($0.46 per share), compared to $23.7 million ($12.04 per share) in Q4 2023; FY 2024 net loss was $49.8 million ($2.34 per share), improved from $70.0 million ($35.71 per share) in FY 2023.

Outlook and guidance

• Cash runway expected to fund operations through post-launch positive operating cash flow.

• Anticipates FDA approval of LNZ100 in August 2025, with commercial launch and product availability in Q4 2025.

• SG&A and sales/marketing expenses expected to continue increasing as launch approaches.

• No significant review issues identified by FDA at mid-cycle review; no Advisory Committee Meeting planned.

• Market exclusivity expected via broad IP portfolio and potential new chemical entity status.